Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Use of continuous glucose monitoring (CGM) systems has become standard of care in type 1 diabetes (T1D) in many countries, particularly in children and adolescents (1,2). Results from clinical trials indicate that use of CGM leads to improved metabolic control and reduction in nonsevere hypoglycemia compared with self-monitoring of capillary blood glucose (3,4). Benefits are seen irrespective of insulin delivery method (pump or pen) (4,5) but are conditioned on near-daily sensor usage (4). Trial participants, however, are often biased toward higher education level, greater therapy adherence, and better self-management. Small sample size and short trial duration very often preclude appropriate assessment of CGM impact on rare events such as severe hypoglycemia (SH) or diabetic ketoacidosis (DKA). We therefore used real-world data from the German-Austrian-Swiss-Luxembourgian Diabetes Prospective Follow-up (DPV) registry to longitudinally assess HbA1c, SH, and DKA during the first year after initiation of CGM, including real-time CGM and intermittently scanned/viewed CGM. Anonymized patient registry records were analyzed. SH was defined as events requiring external assistance by another person and events resulting in coma/convulsion. DKA was defined by pH level <7.3. All HbA1c values were Diabetes Control and Complications Trial (DCCT) standardized. Selection criteria included T1D, 1 year of diabetes duration, available registry data 6 months prior to CGM start (baseline period), and …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185 · cited 2×
“Benefits are seen irrespective of insulin delivery method (pump or pen) (4,5) but are conditioned on”
BackgroundDeSalvo, D. J., Miller, K. M., Hermann, J. M., Maahs, D. M., Hofer, S. E., Clements, M. A., Lilienthal, E., Sherr, J. L., Tauschmann, M., Holl, R. W., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12711 · Cited by 233
Self-citation
Cited by
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery
Sherr, J. L., Schoelwer, M., Dos Santos, T. J., Reddy, L., Biester, T., Galderisi, A., van Dyk, J. C., Hilliard, M. E., Berget, C., & DiMeglio, L. A. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13421 · Cited by 152
Ehrmann, D., Kulzer, B., Roos, T., Haak, T., Al-Khatib, M., & Hermanns, N. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30042-5 · Cited by 141
Cardona-Hernandez, R., Schwandt, A., Alkandari, H., Bratke, H., Chobot, A., Coles, N., Corathers, S., Goksen, D., Goss, P., Imane, Z., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1674 · Cited by 129
Johnson, S. R., Holmes-Walker, D. J., Chee, M., Earnest, A., & Jones, T. W. (2022) · Diabetes Care · doi:10.2337/dc21-1666 · Cited by 86
“Although a definitive answer regarding the impact of CGM on DKA rates could not be determined from the analysis of the overall sample, when the outcomes were limited to those with >75% CGM usage, a reduction in DKA rates was detected, a result consistent with a 1-year study from the Diabetes-Patienten-Verlaufsdokument…”
ResultReal-world evidence of automated insulin delivery system use
Considine, E. G., & Sherr, J. L. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0442 · Cited by 59
“10 A clear and consistent message has emerged with CGM use; it has been clinically instrumental in lowering HbA1C, 4,11–13 increasing time spent in TIR, 13,14 and in reducing rates of severe hypoglycemia and diabetic ketoacidosis, 4,11,14,15 when compared with non-CGM use.”
Metadata
- Authors
- Tauschmann, M., Hermann, J. M., Freiberg, C., Papsch, M., Thon, A., Heidtmann, B., Placzeck, K., Agena, D., Kapellen, T. M., Schenk, B., Wolf, J., Danne, T., Rami-Merhar, B., & Holl, R. W.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-22
- Volume
- 43
- Issue
- 3
- Pages
- e40-e42
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3003006755
- Cited by
- 98
- References
- 2
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry. https://app.cochat.ai/papers/10.2337/dc19-1358
- The paper
- Tauschmann, M., Hermann, J. M., Freiberg, C., Papsch, M., Thon, A., Heidtmann, B., Placzeck, K., Agena, D., Kapellen, T. M., Schenk, B., Wolf, J., Danne, T., Rami-Merhar, B., & Holl, R. W. (2020). Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry. Diabetes Care. https://doi.org/10.2337/dc19-1358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.